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1. Introduction 
More than half of all people living with HIV are women and girls (WHO & UNAIDS, 2010). 
In sub-Saharan Africa, more women than men are living with HIV, and young women aged 
15–24 years are as much as eight times more likely than men to be HIV positive (WHO & 
UNAIDS, 2010). In developed countries, the women who are intravenous drug users, 
partners of drug users or bisexual men, or involved in sex work are more likely to be 
positive for HIV (WHO & UNAIDS, 1999). There are higher proportions of young women 
than young men who acquired HIV infection through sex. Their exposure to the virus at an 
earlier age, coupled with physiological and sociological factors increases their risk (WHO & 
UNAIDS, 1999).    
Globally, HIV is the leading cause of death in women of reproductive age. Since nearly all 
HIV infections in children are acquired from their mothers, the global epidemiology of HIV 
in children reflects that of HIV in women. Nearly all such infections can be prevented by 
programs providing highly effective antiretroviral therapy (ART) and antiretroviral (ARV) 
prophylaxis interventions. 
There are tremendous efforts to control HIV/AIDS and reduce the mortality and morbidity 
rates by improving the accessibility to ART to all HIV- infected patients, trying to eradicate 
the virus from reservoirs of infection and designing an effective vaccine that can elicit 
protective antibody response as well as cell mediated response against HIV (Al-Jabri & Al-
Enzi, 2009). An important step in the fight against HIV/AIDS is to perform antenatal 
screening and counseling. 
2. The importance of antenatal screening and counseling 
HIV testing of individuals should be undertaken only when they are informed about the test 
and should be entirely voluntary. HIV testing and counseling enable women to learn 
whether they are infected, understand their HIV status and make more informed choices for 
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the future. HIV testing and counseling also provide essential knowledge and support: they 
enable uninfected women to remain so, enable those infected with HIV to plan for the future 
and prevent HIV transmission to others. Those who are infected can also benefit from 
available care, treatment and support services. Knowledge of HIV infection leads to initiate 
ART for the long-term treatment of women living with HIV and intervenes with the 
transmission of HIV infections to infants and young children. 
HIV testing in pregnancy is important for many reasons, but this must be balanced against 
the possible risks of stigmatization, discrimination and violence. Voluntary counseling and 
testing should be encouraged for pregnant women and couples. Post-test counseling is 
extremely important following a diagnosis of HIV and should include information about 
pregnancy-related issues and the risk of mother to child transmission (MTCT). Counseling is 
also important for HIV-negative women as it provides an opportunity for risk-reduction. 
HIV-infected women who know their sero-status are able to make informed choices about 
their reproductive lives and, if pregnant, to access specific interventions, such as ARV drugs 
and infant-feeding counseling and support, which can significantly reduce the risk of MTCT 
of HIV. Currently, the majority of people infected with HIV unaware of their status and 
cannot receive the services they actually need.  
A key factor limiting the scale-up of MTCT programs is lack of knowledge of HIV status (Al-
Jabri et al. 2010). Increasing the availability and acceptability of HIV testing and counseling 
services, with no dough, will encourage more women to know their status, providing a 
gateway to MTCT interventions (Bolu et al. 2007). Key factors contributing to the scale-up of 
testing and counseling include a policy of provider-initiated testing and counseling with the 
right to refuse testing; group pretest counseling; rapid HIV testing; innovative staffing 
strategies; and community and male involvement. Integration of testing and counseling 
within the community and all maternal and child health settings are critical for scaling-up 
and for linking women and their families to care and treatment services (Bolu et al. 2007). 
3. Strategies for treatment 
Three types of interventions should be tackled by any program concerned with prevention 
of MTCT: primary prevention of HIV in women; prophylaxis with ARV drugs in 
breastfeeding infants and prophylaxis with ARV drugs for lactating mothers. 
Taking ARV treatment can reduce the risk of MTCT. There are two different ways in which 
drugs can act. First, they may reduce the viral load so the baby is exposed to less of the virus 
while in the uterine and during childbirth. The aim of HIV treatment is to decrease the viral 
load <50 copies/ml. Second, the drugs may cross the placenta and enter the baby’s body, 
where they can prevent the virus from ever taking hold.  
One of the key attainments in HIV research was the demonstration by the Pediatric AIDS 
Clinical Trials Group 076 (PACTG 076) that administration of zidovudine to the pregnant 
woman and her infant could reduce the risk of perinatal transmission (PT) by nearly 70% 
(Connor et al. 1994). Following the results of PACTG 076, implementation of the zidovudine 
regimen coupled with increased antenatal HIV testing and counseling rapidly resulted in 
significant declines in HIV transmission (CDC, 2006). Subsequent clinical trials and 
observational studies showed that combination ARV prophylaxis (initially dual and then 
triple combination therapy) given to the mother antenatally was associated with further 
declines in transmission to less than 2% (Cooper et al. 2002, WHO 2010).  
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4. Mechanisms of action of ARV prophylaxis in reducing perinatal 
transmission of HIV 
There are a number of mechanisms through which zidovudine or other ARV drugs can 
reduce PT. One central mechanism is by decreasing maternal viral load in the blood and 
genital secretions via antenatal drug administration, particularly in women with high viral 
loads. However, ARV drugs have been shown to reduce the risk of transmission even 
among women with HIV RNA levels <1,000 copies/ml (Ioannidis et al. 2001). Additionally, 
the level of HIV RNA at delivery and receipt of antenatal ART are each independently 
associated with the risk of transmission, suggesting that ARV prophylaxis does not work 
solely through reduction in viral load (Sperling et al. 1996).  
An additional mechanism of protection is pre-exposure infant prophylaxis provided by 
administration of ARV drugs that cross the placenta from the mother to the infant, resulting 
in adequate systemic drug levels in the infant. This mechanism of protection is particularly 
significant during the infant’s passage through the birth canal, a time of rigorous exposure 
to maternal genital tract virus. Post-exposure infant prophylaxis is provided through 
administration of drug to the infant after birth. This mechanism protects the infant from cell-
free or cell-associated virus that might have obtained access to the fetal/infant systemic 
circulation. This can occur through maternal-fetal transfusion during uterine contractions in 
labor or through systemic dissemination of virus swallowed by the infant during passage 
through the birth canal.  
It is predictable that efficacy of ARV drugs in reducing PT is multi-factorial, and each of 
these mechanisms is contributory. The efficacy of ARV regimens administered only during 
labor and/or to the newborn in reducing PT demonstrates the importance of the pre- and 
post-exposure components of prophylaxis in reducing PT (Wade et al. 1998).  
5. Perinatal transmission of HIV and maternal viral load 
In PACTG 076, antenatal maternal HIV RNA copy number was associated with HIV 
transmission in women receiving placebo. In women receiving zidovudine, the relationship 
was markedly attenuated and no longer statistically significant (Sperling et al. 1996). An 
HIV RNA threshold below which there was no risk of transmission was not identified; 
zidovudine was effective in reducing transmission regardless of maternal HIV RNA copy 
number (Shapiro et al. 1999). Other data from larger numbers of zidovudine-treated, HIV-
infected pregnant women indicate that HIV RNA levels correlate with risk of transmission 
even in women treated with ARV agents (The European Collaborative Study, 1999).  
Although the risk of PT in women with undetectable HIV RNA levels appears to be 
extremely low, transmission from mother to infant has been reported among women with 
all levels of maternal HIV RNA. Additionally, although HIV RNA may be an important risk 
factor for transmission, other factors also appear to play a role (Mock et al. 1999). Although 
there is a general correlation between viral load in plasma and in the genital tract, 
discordance has also been reported, particularly between HIV proviral load in blood and 
genital secretions, especially in the presence of other genital tract infections (Hart et al. 
1999).   
The use of ARV drugs during pregnancy for prevention of PT should be discussed with and 
offered to all infected pregnant women regardless of their HIV RNA level. Results of 
epidemiologic and clinical trials suggest that women receiving potent combinations of ARV 
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drugs that effectively reduce HIV RNA to <1,000 copies/ml or undetectable levels have very 
low rates of PT (Cooper et al. 2002). However, because transmission can occur even at low 
or undetectable HIV RNA copy numbers, HIV RNA levels should not be a determining 
factor when deciding whether to use ARV drugs for prevention of PT. Additionally, the 
efficacy of ARV drugs is not solely related to lowering viral load (Cooper et al. 2002; 
Ioannidis et al. 2001). Therefore, ARV prophylaxis should be given even to women who 
have a very low or undetectable viral load on no therapy. 
6. Intrapartum ARV therapy/prophylaxis 
6.1 Women who have received antepartum ARV drugs 
The PACTG 076 results and subsequent epidemiologic studies have proven the efficacy of 
the three-part zidovudine chemoprophylaxis regimen alone or in combination with other 
ARV agents. The PACTG 076 zidovudine regimen includes a continuous intravenous 
infusion of zidovudine during labor (initial loading dose of 2 mg/kg intravenously over 1 
hour, followed by continuous infusion of 1 mg/kg/hour until delivery). Therefore, 
intravenous zidovudine during the intrapartum period should be discussed with and 
recommended to all HIV-infected pregnant women. For a scheduled cesarean delivery, 
intravenous zidovudine should begin 3 hours before surgery, according to standard dosing 
recommendations. Women receiving fixed-dose combination regimens that include 
zidovudine (e.g., the zidovudine/lamivudine combination) should have zidovudine 
administered intravenously during labor while other ARV components are continued orally 
(e.g., if a woman is receiving zidovudine/lamivudine during pregnancy, zidovudine should 
be given intravenously and lamivudine should be given orally during labor).  
If known or suspected zidovudine resistance or toxicity has precluded antenatal use of 
zidovudine, intrapartum zidovudine according to the PACTG 076 protocol should still be 
recommended unless a woman has a documented history of hypersensitivity. This 
intrapartum use of the drug is recommended due to the unique characteristics of 
zidovudine and its proven record in reducing PT. 
There is a pharmacologic antagonism between zidovudine and stavudine, and therefore 
these drugs should not be co-administered during labor. Women who are receiving an 
antepartum stavudine-containing regimen should discontinue stavudine during labor while 
intravenous zidovudine is being administered, with other components of the regimen 
continued orally.  
6.2 Women who have received antepartum ARV drugs but have suboptimal viral 
suppression near delivery 
Women who have received ART may not achieve complete viral suppression by the time of 
delivery due to factors such as poor adherence, viral resistance, or late entry into care. 
Regardless of the reason, all women who have HIV RNA levels >1,000 copies/ml near the 
time of delivery should be offered a scheduled cesarean delivery at 38 weeks, which may 
significantly reduce the risk of transmission. 
The addition of single-dose nevirapine during labor has not been shown to reduce PT of 
HIV in this group of women. The PACTG 316 study, conducted in women in the United 
States, Europe, Brazil, and the Bahamas who were receiving ARV drugs during pregnancy 
(primarily combination therapy), showed that the addition of single-dose nevirapine did not 
reduce the risk of MTCT of HIV even in the setting of maternal viremia but was associated 
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with the development of nevirapine resistance in 15% of women with detectable HIV RNA 
postpartum (Cunningham et al. 2002). However, the number of women with detectable HIV 
RNA at delivery, and especially with HIV RNA >10,000 copies/ml, was small and may have 
been insufficient to allow assessment of a possible benefit of single-dose nevirapine in this 
subgroup. Given the risk of development of resistance and the lack of data to suggest added 
efficacy, addition of single-dose nevirapine when a woman has received antepartum drugs 
is generally not recommended.  
6.3 Women who have not received antepartum ARV drugs 
All HIV-infected women who have not received antepartum ART should have intravenous 
zidovudine started immediately to prevent PT of HIV. Although intrapartum/neonatal 
ARTs will not prevent PT that occurs before labor, most transmission occurs near to or 
during labor and delivery. Pre-exposure prophylaxis for the fetus can be provided by giving 
the mother a drug that rapidly crosses the placenta to produce systemic ARV drug levels in 
the fetus during intensive exposure to HIV in maternal genital secretions and blood during 
birth. In general, zidovudine and other NRTI drugs as well as NNRTI drugs cross the 
placenta well, although protease inhibitors drugs do not. 
Epidemiologic data indicate that intravenous maternal intrapartum zidovudine followed by 
oral zidovudine for 6 weeks for the infant significantly reduces transmission compared to no 
treatment (Wade et al. 1998). In a New York State cohort study, transmission rates were 10% 
with intrapartum and neonatal zidovudine compared with 27% without zidovudine, a 62% 
reduction in risk (Wade et al. 1998). The PETRA study demonstrated that intrapartum 
prophylaxis alone, without an infant post-exposure prophylaxis component, is not effective 
in reducing PT (Petra Study Team, 2002).  
Whether the addition of other ARV drugs to the intravenous intrapartum/newborn 
zidovudine regimen when no maternal antepartum drugs have been received increases 
efficacy in preventing PT has not been directly studied. Several intrapartum/neonatal 
prophylaxis regimens have been found to be effective in international studies. These 
include oral zidovudine/lamivudine during labor followed by one week of oral 
zidovudine/lamivudine to the infant and single-dose intrapartum/newborn nevirapine 
(Petra Study Team, 2002). However, none of these regimens has been compared to 
intravenous zidovudine combined with 6 weeks of infant zidovudine prophylaxis.  
Studies need to address whether adding drugs to the intravenous intrapartum/newborn 
zidovudine regimen will enhance efficacy in reducing PT. In the absence of data, some 
experts feel additional drugs may be warranted. One option is to add the single-dose 
intrapartum/newborn nevirapine regimen to the intravenous/6-week infant zidovudine 
regimen. Although single-dose nevirapine did not provide additional efficacy when added 
to antepartum combination ARV regimens in PACTG 316, in this situation, no maternal 
antepartum therapy has been given. Theoretical advantages of combining the zidovudine 
and nevirapine intrapartum/neonatal regimens include the known short-term safety of each 
regimen alone, excellent tranplacental passage of both drugs, greater antiviral activity of 
nevirapine compared to zidovudine, as well as the activity of nevirapine against 
extracellular and intracellular virus (Musoke et al. 1999) and the known synergy of 
zidovudine and nevirapine in inhibiting HIV replication in vitro (Koup et al. 1993). 
However, single-dose nevirapine is associated with the development of nevirapine -resistant 
virus (Jourdain et al. 2004).  
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Studies have shown that nevirapine resistance after intrapartum administration of single-
dose nevirapine can be substantially reduced (but not eliminated) by using a short 
postpartum course of ARV agents from alternate classes (a “tail”). There is no current 
consensus about the exact duration or composition of the ARV tail. Several trials in Africa 
have found 3 to 7 days of maternal/infant postpartum zidovudine/lamivudine to be 
effective (Chaix et al. 2006; McIntyre et al. 2009). Development of resistance to zidovudine or 
lamivudine given for a short period in this setting is rare (Mandelbrot et al. 2001).  
More recent studies have found that 7 days of tenofovir/emtricitabine (TEmAA ANRS 
12109 Study Group, 2009), 7 days of zidovudine/didanosine/lopinavir-ritonavir (Van Dyke 
et al. 2009), and 30 days of zidovudine/didanosine or zidovudine/didanosine/lopinavir-
ritonavir (Lallemant et al. 2010) all appear to be effective at reducing the development of 
nevirapine resistance.  
7. The efficiency of current anti-HIV treatments 
The efficacy of ARV drugs in preventing MTCT of HIV varies with the type of regimen used 
and the duration over which it is given. Combination regimens which include different 
types of ARV drugs are more efficacious than monotherapies as discussed above. It is well 
known that monotherapies can lead to ARV resistance in the virus, which may limit future 
therapeutic options when treatment is needed. According to the 2010 WHO treatment 
guidelines it is recommended that pregnant women living with HIV and their exposed 
infants receive combination therapy rather than single-dose nevirapine. ARV prophylaxis is 
also recommended during breastfeeding in settings where breastfeeding is judged to be the 
safest infant feeding option. In addition, all women eligible for treatment under WHO 
guidelines should receive an appropriate combination therapy for their own health (WHO, 
2010). 
8. Practice and procedures 
Three types of interventions should be tackled by any program concerned with prevention 
of mother-to-child transmission of HIV: primary prevention of HIV-1 in women; 
prophylaxis with ARV drugs in breastfeeding infants and prophylaxis with ARV drugs for 
lactating mothers. Administration of zidovudine to the pregnant woman and her infant 
could reduce the risk of perinatal transmission by nearly 70%. Combination ARV 
prophylaxis given to the mother antenatally is associated with further declines in 
transmission to <2%. Combination regimens are more effective than single-drug regimens in 
reducing perinatal transmission.  
9. Chapter key facts 
 Zidovudine administration to the pregnant woman and her infant can reduce the risk of 
perinatal transmission by nearly 70%.  
 Combination regimens are more effective than single-drug regimens in reducing 
perinatal transmission. A longer three-part regimen given antenatally, intrapartum, and 
postpartum is superior in preventing perinatal transmission than a shorter two-part 
antepartum/intrapartum or intrapartum/postpartum regimen. 
 The standard recommendation for infant prophylaxis in the absence of maternal 
antenatal and intrapartum therapy is six weeks of infant zidovudine. The addition of 
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single-dose intrapartum nevirapine is generally not recommended for women who are 
receiving the standard recommended antenatal antiretroviral prophylaxis regimens. 
 Antiretroviral prophylaxis should be given to women who have a very low or 
undetectable viral load on no therapy. 
 Intravenous zidovudine during the intrapartum period should be discussed with and 
recommended to all HIV-infected pregnant women. 
10. Summary points of chapter 
 HIV is the leading cause of death in women of reproductive age. 
 HIV testing and counseling should be undertaken and should be entirely voluntary. 
 Three types of interventions should be tackled by any program concerned with 
prevention of mother-to-child transmission: primary prevention of HIV in women; 
prophylaxis with antiretroviral drugs in breastfeeding infants and prophylaxis with 
antiretroviral drugs for lactating mothers. 
 Taking antiretroviral treatment can reduce the risk of mother-to-child transmission. 
 Administration of zidovudine to the pregnant woman and her infant could significantly 
reduce the risk of perinatal transmission.  
 Combination antiretroviral prophylaxis (initially dual and then triple combination 
therapy) given to the mother antenatally can further declines the transmission 
significantly. 
 Regardless of the reason, all women who have HIV RNA levels >1,000 copies/ml near 
the time of delivery should be offered a scheduled cesarean delivery at 38 weeks, which 
may significantly reduce the risk of transmission. 
 Given the risk of development of resistance, addition of single-dose nevirapine when a 
woman has received antepartum drugs is generally not recommended.  
11. Definitions and explanations of words and terms 
Antenatal Before birth 
Antepartum  Before labour or child birth 
Antiretroviral  Drugs used for the treatment of antiretroviral infections 
Antiretroviral Therapy Drugs used against retroviruses such as HIV 
Intrapartum During labour and delivery or childbirth 
Intravenous Occurring or introduced to within a vein or veins usually 
by means of injection  
Labour The process of child birth 
Microbicides An agent destructive to microbes 
Monotherapy  Single drug treatment 
Mother to child transmission Is the transfer of an agent (e.g. HIV) from the mother to 
her unborn or born baby 
Perinatal  Occurring during , or pertaining to, the periods before, 
during, or after the time of birth i.e. before delivery from 
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the 28th week of gestation through the first 7 days after 
delivery  
Pharmacologic Antagonism Opposition in action of drugs 
Prophylaxis Protection treatment against disease 
Viral Resistance The development of mutation within the virus genome 
that leads to the virus becoming resistance to the drug 
treatment 
12. List of abbreviations 
ART  Antiretroviral Therapy 
ARV  Antiretroviral  
PT  Perinatal Transmission 
RNA  Ribonucleic acid 
UNAIDS United Nations AIDS  
NRTI  Nucleoside reverse transcriptase inhibitors 
NNRTI  Non-nucleoside reverse transcriptase inhibitors 
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Like any other book on the subject of HIV/AIDS, this book is not a substitute or exhausting the subject in
question. It aims at complementing what is already in circulation and adds value to clarification of certain
concepts to create more room for reasoning and being part of the solution to this global pandemic. It is further
expected to complement a wide range of studies done on this subject, and provide a platform for the more
updated information on this subject. It is the hope of the authors that the book will provide the readers with
more knowledge and skills to do more to reduce HIV transmission and improve the quality of life of those that
are infected or affected by HIV/AIDS.
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